ReviewFrontiers in microbiology2025
Antibacterial nanoagents: an emerging arsenal against bacterial persisters.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advanced Nanomaterials for Chronic Wounds: M.O.I.S.T. Concept-Driven Design Strategy.Advanced healthcare materials · 2026Review
- The Pharmacology of Bacterial Persistence: From Antibiotic Tolerance to Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Combating Bacterial Infection with Metabolism-Regulating Nanomaterials.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial persisters represent a metabolically dormant or slow-growing subpopulation within bacterial communities that exhibit resistance to antibiotics. These cells are capable of resuming active proliferation upon the removal of environmental stressors, hence serving as reservoirs for recurrent infections. Extensive clinical evidence links persister cell formation with chronic infection and post-therapeutic recurrence. In this minireview, we highlight the challenges in eradicating persisters and review recent advances in nanomaterial-based antimicrobial strategies that specifically target these resilient cells. We also discuss key translational barriers impeding the clinical application of antibacterial nanoagents. By integrating these insights, we aim to provide a conceptual roadmap for the development of next-generation therapies against persistent bacterial infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.